Salarius Pharmaceuticals Points Out Mistakes on S&P CapIQ Platform After Merging with Decoy Therapeutics, Confirms Its Shares Remain Listed on Nasdaq Under the Symbol "SLRX"

Correction of Misinformation: Salarius Pharmaceuticals addresses an error on the S&P CapIQ platform that incorrectly stated the company had been delisted from Nasdaq, confirming that its stock continues to trade under the ticker "SLRX."

Recent Financial Activities: The company completed an $8 million public offering and merged with Decoy Therapeutics, resulting in a combined cash position of approximately $14 million and around 5.9 million shares outstanding.

Focus on Drug Development: Salarius is advancing Decoy's pipeline of peptide conjugate therapeutics, utilizing its IMP3ACT platform, which incorporates AI and machine learning to streamline drug development.

Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future plans and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.